The Manufacturers Life Insurance Company Purchases 55,672 Shares of Stoke Therapeutics, Inc. $STOK

Key Points

• Manulife increased its Stoke Therapeutics stake by 410.9% in the first quarter, purchasing 55,672 shares to reach 69,222 shares valued at approximately $2.25 million.
• Stoke reported a quarterly loss of $0.93 per share, missing the $0.80 consensus estimate, although revenue of $9.32 million exceeded expectations. The company remains deeply unprofitable, with analysts forecasting a full-year loss of $3.50 per share.
• Analyst sentiment remains broadly positive, with nine Buy ratings and an average target price of $43 versus a recent share price of $32.71. However, insiders sold 10,428 shares worth about $307,000 over the past 90 days, including a 7,176-share sale by director Barry Ticho under a pre-arranged trading plan.

The Manufacturers Life Insurance Company lifted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 410.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,222 shares of the company's stock after buying an additional 55,672 shares during the period. The Manufacturers Life Insurance Company owned about 0.11% of Stoke Therapeutics worth $2,254,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC grew its position in Stoke Therapeutics by 1.2% during the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company's stock valued at $935,000 after acquiring an additional 354 shares during the last quarter. Strs Ohio lifted its holdings in shares of Stoke Therapeutics by 9.4% in the 4th quarter. Strs Ohio now owns 7,000 shares of the company's stock worth $222,000 after acquiring an additional 600 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company's stock worth $88,000 after acquiring an additional 658 shares during the last quarter. Generali Investments Management Co LLC boosted its stake in shares of Stoke Therapeutics by 41.0% in the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company's stock valued at $78,000 after purchasing an additional 718 shares in the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Stoke Therapeutics by 0.5% in the 1st quarter. First Trust Advisors LP now owns 163,459 shares of the company's stock valued at $5,322,000 after purchasing an additional 780 shares in the last quarter.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $32.71 on Friday. Stoke Therapeutics, Inc. has a 52-week low of $12.86 and a 52-week high of $40.22. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -9.79 and a beta of 1.20. The company's 50 day moving average price is $30.45 and its 200-day moving average price is $32.05.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, equities research analysts forecast that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 1,457 shares of the firm's stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total value of $43,637.15. Following the sale, the general counsel directly owned 18,086 shares of the company's stock, valued at $541,675.70. This trade represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 7,176 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $29.04, for a total value of $208,391.04. Following the transaction, the insider owned 20,422 shares in the company, valued at approximately $593,054.88. This represents a 26.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 10,428 shares of company stock worth $306,919 in the last 90 days. Corporate insiders own 9.60% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on STOK shares. BTIG Research reaffirmed a "buy" rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Chardan Capital restated a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. The Goldman Sachs Group assumed coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They set a "buy" rating and a $44.00 price target for the company. Weiss Ratings cut Stoke Therapeutics from a "hold (c)" rating to a "sell (d)" rating in a research note on Monday, May 11th. Finally, Guggenheim reiterated a "buy" rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Stoke Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $43.00.

Key Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target on STOK to $40 while maintaining an “outperform” rating, signaling confidence in the company’s pipeline and potential upside. Wedbush raises Stoke Therapeutics price target
• Positive Sentiment: Chardan Capital reiterated a “buy” rating on Stoke Therapeutics, adding to the favorable analyst sentiment surrounding the biotechnology company. Chardan Capital buy rating
• Neutral Sentiment: Canaccord Genuity remained constructive on the shares but issued a more cautious price outlook, reflecting a mixed analyst view despite continued confidence in Stoke’s long-term prospects. Canaccord Genuity forecast for Stoke Therapeutics
• Negative Sentiment: HC Wainwright cut its projected EPS for fiscal 2026 to a loss of $3.35 from $3.09, fiscal 2027 to a loss of $2.55 from $2.05, and fiscal 2028 to a loss of $1.78 from $0.67. It also reduced quarterly estimates to losses of $0.81 per share, indicating expectations for higher or more prolonged expenses. HC Wainwright earnings forecast for Stoke Therapeutics
• Negative Sentiment: HC Wainwright’s broader outlook remains bearish for later years, with its FY2029 EPS forecast reportedly reduced to $1.55 from $1.63. The revisions highlight execution and commercialization risks for Stoke’s pipeline. HC Wainwright FY2029 forecast
• Negative Sentiment: Director Barry Ticho sold 7,176 shares worth approximately $208,000, reducing his direct holdings by 26%. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, its negative signaling value is limited, but it may still weigh modestly on sentiment. SEC insider sale filing

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source